A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
NCT ID: NCT00909597
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
756 participants
INTERVENTIONAL
2009-05-31
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pioglitazone
pioglitazone
30mg po once daily for 4 weeks, followed by 45mg once daily
taspoglutide 10mg
taspoglutide 10mg sc weekly
taspoglutide
10mg sc once weekly
taspoglutide 10mg/20mg
taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly
taspoglutide
10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pioglitazone
30mg po once daily for 4 weeks, followed by 45mg once daily
taspoglutide
10mg sc once weekly
taspoglutide
10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* type 2 diabetes mellitus;
* treated with stable sulfonylurea monotherapy or metformin + sulfonylurea for \>=12 weeks prior to screening;
* HbA1c \>=7.0% and \<=10% at screening;
* stable weight +/-5% for \>=12 weeks prior to screening.
Exclusion Criteria
* clinically significant diabetic complications;
* clinically symptomatic gastrointestinal disease;
* \>3 episodes of severe hypoglycemia within 6 months before screening.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Buena Park, California, United States
Chino, California, United States
Los Angeles, California, United States
Rancho Cucamonga, California, United States
Roseville, California, United States
Santa Ana, California, United States
Chiefland, Florida, United States
Coral Gables, Florida, United States
Daytona Beach, Florida, United States
Panama City, Florida, United States
Port Charlotte, Florida, United States
St. Petersburg, Florida, United States
Winter Park, Florida, United States
Atlanta, Georgia, United States
Columbus, Georgia, United States
Conyers, Georgia, United States
Roswell, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Springfield, Illinois, United States
Evansville, Indiana, United States
Madisonville, Kentucky, United States
Metairie, Louisiana, United States
Bethesda, Maryland, United States
Ayer, Massachusetts, United States
Waltham, Massachusetts, United States
Ferndale, Michigan, United States
Minneapolis, Minnesota, United States
Biloxi, Mississippi, United States
Jackson, Mississippi, United States
Olive Branch, Mississippi, United States
Grand Island, Nebraska, United States
Berlin, New Jersey, United States
Brick, New Jersey, United States
Toms River, New Jersey, United States
Trenton, New Jersey, United States
New York, New York, United States
Staten Island, New York, United States
Durham, North Carolina, United States
Mooresville, North Carolina, United States
Winston-Salem, North Carolina, United States
Fargo, North Dakota, United States
Bend, Oregon, United States
Medford, Oregon, United States
Beaver, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Scranton, Pennsylvania, United States
Kingsport, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
South Burlington, Vermont, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Spokane, Washington, United States
Vancouver, Washington, United States
Waukesha, Wisconsin, United States
Camperdown, New South Wales, Australia
Wollongong, New South Wales, Australia
Fortaleza, Ceará, Brazil
Lago Sul, Federal District, Brazil
Belo Horizonte, Minas Gerais, Brazil
Marília, São Paulo, Brazil
São Paulo, São Paulo, Brazil
São Paulo, São Paulo, Brazil
São Paulo, São Paulo, Brazil
São Paulo, São Paulo, Brazil
Sorocaba, São Paulo, Brazil
Vancouver, British Columbia, Canada
Etobicoke, Ontario, Canada
London, Ontario, Canada
Thornhill, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
San José, , Costa Rica
San José, , Costa Rica
Besançon, , France
Corbeil-Essonnes, , France
Dommartin-lès-Toul, , France
La Rochelle, , France
Lille, , France
Poitiers, , France
Vénissieux, , France
Berlin, , Germany
Essen, , Germany
Falkensee, , Germany
Mainz, , Germany
Münster, , Germany
Rodgau, , Germany
Siegen, , Germany
Sulzbach-Rosenberg, , Germany
Wangen, , Germany
Aguascaliente, , Mexico
Celaya, , Mexico
Cuernavaca, , Mexico
Guadalajara, , Mexico
Guadalajara, , Mexico
Mexico City, , Mexico
Monterrey, , Mexico
Auckland, , New Zealand
Auckland, , New Zealand
San Isidro, , Peru
Gdansk, , Poland
Krakow, , Poland
Krakow, , Poland
Lublin, , Poland
Lublin, , Poland
Wroclaw, , Poland
Rio Piedras, , Puerto Rico
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Penza, , Russia
S.Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saratov, , Russia
Voronezh, , Russia
Yaroslavl, , Russia
Yaroslavl, , Russia
Bratislava, , Slovakia
Dolný Kubín, , Slovakia
Levice, , Slovakia
Levice, , Slovakia
Cape Town, , South Africa
Almería, Almeria, Spain
Barcelona, Barcelona, Spain
Pamplona, Navarre, Spain
Oviedo, Principality of Asturias, Spain
Barakaldo, Vizcaya, Spain
Chiang Mai, , Thailand
Pathum Thani, , Thailand
Songkhla, , Thailand
Kiev, , Ukraine
Odesa, , Ukraine
Odesa, , Ukraine
Vinnitsa, , Ukraine
Atherstone, , United Kingdom
Birmingham, , United Kingdom
Chesterfield, , United Kingdom
Dumfries, , United Kingdom
Glasgow, , United Kingdom
Hinckley, , United Kingdom
Reading, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-009157-24
Identifier Type: -
Identifier Source: secondary_id
BC21893
Identifier Type: -
Identifier Source: org_study_id